Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia (FAST Registry)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03376438|
Recruitment Status : Recruiting
First Posted : December 18, 2017
Last Update Posted : December 18, 2017
|Condition or disease||Intervention/treatment|
|Atrial Flutter Tachycardia, Supraventricular Tachycardia, Atrial Ectopic Tachycardia, Reciprocating Tachycardia Atrial Tachycardia, Atrioventricular Nodal Reentry Tachycardia, Paroxysmal Fetal Hydrops||Other: Prospective observational cohorts|
Few studies are specifically designed to address health concerns relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally fast heart rate up to 300 beats per minute due to supraventricular tachyarrhythmia (SVA) in the unborn baby (fetus). Although fetal SVA, including AF and other forms of SVT, is the most common cause of intended in-utero fetal therapy, our knowledge of drug effects on the baby and the co-treated mother is still limited. The Fetal Atrial Flutter and Supraventricular Tachycardia (FAST) Therapy Trial is a prospective multi-center trial to address this knowledge gap in order to guide future patient management to the best of care.
FAST Trial components include:
- A prospective Registry (FAST Registry; see this document) as well as
- Three prospective Randomized Clinical Trials (FAST RCTs; see ClinicalTrials.gov #NCT02624765).
The FAST Registry is a prospective observational cohort study to determine the impact of different prenatal treatment strategies on patients diagnosed with fetal AF without hydrops, AF with hydrops, SVT without hydrops, and SVT with hydrops. All management decisions including the choice of antiarrhythmic medication or the decision to observe without treatment are at the discretion of the treating physician. The primary outcome measure will be the proportion of term deliveries of live-born children with a normal cardiac rhythm. Secondary outcome measures include the efficacy of 1st line, 2nd line, 3rd line, and maintenance drug therapy in controlling the different arrhythmias prior to birth and patient safety.
Participation of a site in the FAST Registry requires experience with the perinatal management of fetal AF and SVT, local REB/IRB approval and an executed legal contract with the Hospital for Sick Children, Toronto.
Participation of a patient in the FAST Registry requires that all inclusion and none of the exclusion criteria are fulfilled (see below). Enrollment is possible within 2 days of the arrhythmia diagnosis and the initial management decision.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||FAST Trial Registry: Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia|
|Actual Study Start Date :||June 8, 2017|
|Estimated Primary Completion Date :||May 31, 2027|
|Estimated Study Completion Date :||May 31, 2027|
Prospective observational cohorts
1) Atrial flutter without fetal hydrops; 2) Atrial flutter with fetal hydrops; 3) Supraventricular tachycardia without fetal hydrops; and 4) Supraventricular tachycardia with fetal hydrops
Other: Prospective observational cohorts
Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
Other Name: Non-randomized antiarrhythmic fetal drug therapy
- Proportion of live-born children with a delivery at term and a normal cardiac rhythm [ Time Frame: Term: 37 0/7 to 41 6/7 weeks ]
- Proportion of patients with cardioversion over time [ Time Frame: From date of SVA dignosis until the date of first documented cardioversion or until the date of delivery/fetal death without cardioversion, whichever comes first, assessed up to 30 gestational weeks ]Number of participants with persistent tachycardia compared to number of participants with cardioversion to a normal rhythm over time
- Proportion of participants with treatment failure [ Time Frame: From date of treatment start until the date of first documented fetal cardioversion or until the date of treatment failure, whichever comes first, assessed up to 30 gestational weeks ]Number of participants with treatment failure compared to number of participants with successful treatment. Treatment failure is defined as one of the following: 1) cross-over to another drug; 2) SVT/AF that persists to birth; 3) preterm birth; 4) death.
- Proportion of participants with arrhythmia-related death [ Time Frame: From date of arrhythmia diagnosis or date of treatment start to 30 days of life ]Number of participants with arrhythmia-related death compared to other outcomes
- Average gestational age at birth [ Time Frame: At birth ]
- Birth weight (z-scores; centiles) [ Time Frame: At birth ]
- Total days of treatment related maternal and neonatal hospitalizations [ Time Frame: From date of diagnosis or treatment begin to 30 days of life ]
- Maternal prevalence of pregnancy/treatment-related AEs and outcomes [ Time Frame: Diagnosis to birth ]
- Maternal prevalence of adverse events and outcome [ Time Frame: From date of treatment begin to 30 days of life ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376438
|Contact: Sarah Selvadurai, MSc||416-813-7654 ext 228624||FAST.Trial@sickkids.ca|
|Contact: Beren Avci, M.A., CCRP||416-813-7654 ext 309423||FAST.Trial@sickkids.ca|
|The Hospital for Sick Children||Recruiting|
|Toronto, Ontario, Canada, M5G1X8|
|Contact: Edgar Jaeggi, MD 416-813-7500 email@example.com|
|Contact: Sarah Selvadurai, MSc 416-813-7654 ext 228624 FAST.Trial@sickkids.ca|
|Principal Investigator: Edgar Jaeggi, MD|
|Sub-Investigator: Fraser Golding, MD|
|Sub-Investigator: Varsha Thakur, MD|
|Sub-Investigator: Vitor Guerra, MD|
|Sub-Investigator: Mike Seed, MD|
|Sub-Investigator: Luc Mertens, MD|
|Sub-Investigator: Mark Friedberg, MD|
|Principal Investigator:||Edgar Jaeggi, MD, FRCPC||The Hospital for Sick Children, Toronto, ON, Canada|